Despite—or perhaps because of—the high prevalence of EGFR amplification and overexpression in HNSCC, several clinical studies failed to demonstrate enhanced sensitivity to cetuximab in amplified or overexpressing populations [49,58]. Here, EGFR is linked to head and neck squamous cell carcinoma.